Panic Disorder Market Report and Forecast 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Panic Disorder Overview 
    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Panic Disorder Epidemiology Analysis – 7MM
    5.1    7MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States Panic Disorder Epidemiology Forecast (2017-2032)
    5.3    EU-4 and United Kingdom Panic Disorder Epidemiology Forecast (2017-2032)
        5.3.1    Germany Panic Disorder Epidemiology Forecast (2017-2032)
        5.3.2    France Panic Disorder Epidemiology Forecast (2017-2032)
        5.3.3    Italy Panic Disorder Epidemiology Forecast (2017-2032)
        5.3.4    Spain Panic Disorder Epidemiology Forecast (2017-2032)
        5.3.5    United Kingdom Panic Disorder Epidemiology Forecast (2017-2032)
    5.4    Japan Panic Disorder Epidemiology Forecast (2017-2032)
6    Panic Disorder Market Overview – 7MM
    6.1    Panic Disorder Market Historical Value (2017-2023) 
    6.2    Panic Disorder Market Forecast Value (2024-2032)
7    Panic Disorder Market Landscape – 7MM
    7.1    Panic Disorder Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Panic Disorder Product Landscape
        7.2.1    Analysis by Diseases Type
        7.2.2    Analysis by Drug Class
        7.2.3    Analysis by Route of Administration
8    Panic Disorder Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Panic Disorder Market Dynamics
    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Panic Disorder Market Segmentation – 7MM
    11.1    Panic Disorder Market by Type
        11.1.1    Market Overview
        11.1.2    Agoraphobia
        11.1.3    Social Anxiety Disorder (SAD)
        11.1.4    Obsessive-Compulsive Disorder (OCD)
        11.1.5    Bipolar Disorder
        11.1.6    Post-Traumatic Stress Disorder (PTSD)
        11.1.7    Specific Phobias, Generalized Anxiety Disorder (GAD)
        11.1.8    Major Depressive Disorder (MDD)
        11.1.9    Others
    11.2    Panic Disorder Market by Therapy
        11.2.1    Market Overview
        11.2.2    Electroconvulsive Therapy ECT
        11.2.3    Cognitive-Behavioral Therapy (CBT)
    11.3    Panic Disorder Market by Drug Class
        11.3.1    Market Overview
        11.3.2    Benzodiazepines (BZD)
        11.3.3    Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
        11.3.4    Monoamine Oxidase Inhibitors (MAOIs)
        11.3.5    Anti-Depressants
        11.3.6    Tricyclic Antidepressants (TCAs)
        11.3.7    Pregabalin
        11.3.8    Buspirone
        11.3.9    Sertraline
        11.3.10    Others
    11.4    Panic Disorder Market by Route of Administration
        11.4.1    Market Overview
        11.4.2    Oral
        11.4.3    Parenteral
    11.5    Panic Disorder Market by Region
        11.5.1    Market Overview
        11.5.2    United States
        11.5.3    EU-4 and the United Kingdom
            11.5.3.1    Germany
            11.5.3.2    France
            11.5.3.3    Italy
            11.5.3.4    Spain
            11.5.3.5    United Kingdom    
        11.5.4    Japan
12    United States Panic Disorder Market
    12.1    Panic Disorder Market Historical Value (2017-2023) 
    12.2    Panic Disorder Market Forecast Value (2024-2032)
    12.3    Panic Disorder Market by Disease Type
    12.4    Panic Disorder Market by Treatment Type
13    EU-4 and United Kingdom Panic Disorder Market
    13.1    Panic Disorder Market Historical Value (2017-2023) 
    13.2    Panic Disorder Market Forecast Value (2024-2032)
    13.3    Germany Panic Disorder Market Overview
        13.3.1    Panic Disorder Market by Disease Type
        13.3.2    Panic Disorder Market by Treatment Type
    13.4    France Panic Disorder Market Overview
        13.4.1    Panic Disorder Market by Disease Type
        13.4.2    Panic Disorder Market by Treatment Type
    13.5    Italy Panic Disorder Market Overview
        13.5.1    Panic Disorder Market by Disease Type
        13.5.2    Panic Disorder Market by Treatment Type
    13.6    Spain Panic Disorder Market Overview
        13.6.1    Panic Disorder Market by Disease Type
        13.6.2    Panic Disorder Market by Treatment Type
    13.7    United Kingdom Panic Disorder Market Overview
        13.7.1    Panic Disorder Market by Disease Type
    13.8    Panic Disorder Market by Treatment Type
14    Japan Panic Disorder Market
    14.1    Panic Disorder Market Historical Value (2017-2023) 
    14.2    Panic Disorder Market Forecast Value (2024-2032)
    14.3    Panic Disorder Market by Disease Type
    14.4    Panic Disorder Market by Treatment Type
15    Patent Analysis
    15.1    Analysis by Type of Patent
    15.2    Analysis by Publication year
    15.3    Analysis by Issuing Authority
    15.4    Analysis by Patent Age
    15.5    Analysis by CPC Analysis
    15.6    Analysis by Patent Valuation 
    15.7    Analysis by Key Players
16    Grants Analysis
    16.1    Analysis by year
    16.2    Analysis by Amount Awarded
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Grant Application
    16.5    Analysis by Funding Institute
    16.6    Analysis by NIH Departments
    16.7    Analysis by Recipient Organization 
17    Clinical Trials Analysis
    17.1     Analysis by Trial Registration Year
    17.2    Analysis by Trial Status
    17.3    Analysis by Trial Phase
    17.4    Analysis by Therapeutic Area
    17.5    Analysis by Geography
18    Funding Analysis
    18.1    Analysis by Funding Instances
    18.2    Analysis by Type of Funding
    18.3    Analysis by Funding Amount
    18.4    Analysis by Leading Players
    18.5    Analysis by Leading Investors
    18.6    Analysis by Geography
19    Partnership and Collaborations Analysis
    19.1    Analysis by Partnership Instances
    19.2    Analysis by Type of Partnership
    19.3    Analysis by Leading Players
    19.4    Analysis by Geography
20    Supplier Landscape
    20.1    Teva Pharmaceutical Industries Ltd
        20.1.1    Financial Analysis
        20.1.2    Product Portfolio
        20.1.3    Demographic Reach and Achievements
        20.1.4    Mergers and Acquisition
        20.1.5    Certifications
    20.2    Sun Pharmaceutical Industries Ltd.
        20.2.1    Financial Analysis
        20.2.2    Product Portfolio
        20.2.3    Demographic Reach and Achievements
        20.2.4    Mergers and Acquisition
        20.2.5    Certifications
    20.3    Mylan
        20.3.1    Financial Analysis
        20.3.2    Product Portfolio
        20.3.3    Demographic Reach and Achievements
        20.3.4    Mergers and Acquisition
        20.3.5    Certifications
    20.4    AstraZeneca
        20.4.1    Financial Analysis
        20.4.2    Product Portfolio
        20.4.3    Demographic Reach and Achievements
        20.4.4    Mergers and Acquisition
        20.4.5    Certifications
    20.5    Abbott
        20.5.1    Financial Analysis
        20.5.2    Product Portfolio
        20.5.3    Demographic Reach and Achievements
        20.5.4    Mergers and Acquisition
        20.5.5    Certifications
        20.5.6    BaxterFinancial Analysis
        20.5.7    Product Portfolio
        20.5.8    Demographic Reach and Achievements
        20.5.9    Mergers and Acquisition
        20.5.10    Certifications
    20.6    Baxter
        20.6.1    Financial Analysis
        20.6.2    Product Portfolio
        20.6.3    Demographic Reach and Achievements
        20.6.4    Mergers and Acquisition
        20.6.5    Certifications
    20.7    Bristol-Myers Squibb Company
        20.7.1    Financial Analysis
        20.7.2    Product Portfolio
        20.7.3    Demographic Reach and Achievements
        20.7.4    Mergers and Acquisition
        20.7.5    Certifications
    20.8    Eli Lilly and Company
        20.8.1    Financial Analysis
        20.8.2    Product Portfolio
        20.8.3    Demographic Reach and Achievements
        20.8.4    Mergers and Acquisition
        20.8.5    Certifications
    20.9    F. Hoffmann-La Roche Ltd
        20.9.1    Financial Analysis
        20.9.2    Product Portfolio
        20.9.3    Demographic Reach and Achievements
        20.9.4    Mergers and Acquisition
        20.9.5    Certifications
    20.10    GlaxoSmithKline plc
        20.10.1    Financial Analysis
        20.10.2    Product Portfolio
        20.10.3    Demographic Reach and Achievements
        20.10.4    Mergers and Acquisition
        20.10.5    Certifications
    20.11    Recordati S.p.A. 
        20.11.1    Financial Analysis
        20.11.2    Product Portfolio
        20.11.3    Demographic Reach and Achievements
        20.11.4    Mergers and Acquisition
        20.11.5    Certifications
    20.12    Boehringer Ingelheim International GmbH. 
        20.12.1    Financial Analysis
        20.12.2    Product Portfolio
        20.12.3    Demographic Reach and Achievements
        20.12.4    Mergers and Acquisition
        20.12.5    Certifications
    20.13    Neurocrine Biosciences, Inc
        20.13.1    Financial Analysis
        20.13.2    Product Portfolio
        20.13.3    Demographic Reach and Achievements
        20.13.4    Mergers and Acquisition
        20.13.5    Certifications
    20.14    Recordati S.p.A. 
        20.14.1    Financial Analysis
        20.14.2    Product Portfolio
        20.14.3    Demographic Reach and Achievements
        20.14.4    Mergers and Acquisition
        20.14.5    Certifications
    20.15    Sanofi 
        20.15.1    Financial Analysis
        20.15.2    Product Portfolio
        20.15.3    Demographic Reach and Achievements
        20.15.4    Mergers and Acquisition
        20.15.5    Certifications
21    Panic Disorders Market - Distribution Model (Additional Insight)
    21.1    Overview 
    21.2    Potential Distributors 
    21.3    Key Parameters for Distribution Partner Assessment 
22    Key Opinion Leaders (KOL) Insights (Additional Insight)
23    Company Competitiveness Analysis (Additional Insight)
    23.1    Very Small Companies
    23.2    Small Companies
    23.3    Mid-Sized Companies
    23.4    Large Companies
    23.5    Very Large Companies
24    Payment Methods (Additional Insight)
    24.1    Government Funded
    24.2    Private Insurance
    24.3    Out-of-Pocket

    
*Additional insights provided are customisable as per client requirements.